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Glomerular VEGF expression is critical for the maintenance and function of an intact ﬁltration barrier. Alterations in glomerular
VEGF bioavailability result in endothelial as well as in podocyte damage. Renal involvement in preeclampsia includes proteinuria,
podocyturia, elevated blood pressure, edema, glomerular capillary endotheliosis, and thrombotic microangiopathy. At least the
renal signs, symptoms, and other evidence can suﬃciently be explained by reduced VEGF levels. The aim of this paper was to
summarize our pathophysiological understanding of the renal involvement of preeclampsia and point out similarities to the renal
side eﬀects of VEGF-ablation therapy.
1.Introduction
The renal involvement in preeclampsia is characterized by
hypertension and proteinuria that have to present after the
twentiethweekofgestationtofulﬁltheclinicaldiagnosis.Itis
alsoassociatedwithedemaandhyperuricemia[1].Glomeru-
lar capillary endotheliosis and thrombotic microangiopathy
(TMA) are more severe ﬁndings. The pathophysiology of
thesephenomenaisexplained byexcessplacentalsolublefms
like tyrosin kinase-1 (sFlt-1) that binds circulating vascular
endothelial growth factor (VEGF) and placenta growth
factor (PlGF) and prevents their interaction with endothelial
cell-surface receptors. sFlt-1 is also known as soluble VEGF
receptor-1 (sVEGFR-1). Other abbreviations for PlGF are
PGF and PLGF.
VEGF is a potent promoter of angiogenesis; it regu-
lates endothelial cell function by induction of nitric oxide
and vasodilatation and decreases vascular tone and blood
pressure [2]. The major source of glomerular VEGF under
normalconditionsisthepodocyte[3].Duringpregnancythe
placenta is the main source of sFlt-1 and PIGF.
In 2003, Maynard et al. observed that the serum levels
of both VEGF and PlGF were decreased in women with
preeclampsia. However, the magnitude of decrease was less
pronounced for VEGF since its serum level was not as
high as PlGF, even in normal pregnancy [4]. De Vivo et al.
showed that Endoglin, PlGF, and sFlt-1 might be used as
markers for predicting preeclampsia and that sFlt-1:PlGF-
ratio is even more accurate [5]. Eventually measurement of
antiangiogenic factors might become a surrogate for renal
biopsy to establish the diagnosis.
Under pathological conditions VEGF is produced by
various cancers to induce angiogenesis and supply the
tumour with new blood vessels. In the last years anti-VEGF
therapies that either block the extracellular binding of VEGF
toitsreceptor(anti-VEGFantibodies)orinhibitintracellular
signalling pathways of VEGF receptors (receptor tyrosine
kinase inhibitors) have become an innovative target in the
treatment of these cancers.
Since the only receptor for PIGF is VEGFR-1, antian-
giogenetic targets blocking this receptor inhibit both VEGF
signalling as well as the PLGF pathway.
In oncology trials that antagonize VEGF using neutral-
izing antibodies and VEGF receptor inhibitors hypertension,
proteinuria and TMA can also occur similar to the phenom-
ena seen in preeclampsia [6, 7].
First evidence for similarities between preeclampsia and
side eﬀects of VEGF ablation therapy in the kidney emerged2 Journal of Pregnancy
from studies in animals. An adenovirus-expressing sFlt-
1 in rodents caused a clinical syndrome with features of
preeclampsia, including glomerular endotheliosis, protein-
uria, and hypertension [4].
In an institutional review board-approved case series
Patel et al. described seven patients who developed a
“preeclampsia-likesyndrome”characterizedbyhypertension
and proteinuria after starting therapy with sunitinib and
sorafenib, two multityrosine kinase inhibitors interfering
with VEGF signalling. The patients were identiﬁed clinically
after developing edema, hypertension, proteinuria, and/or
hypoalbuminemia [8].
In the following sections, we will highlight the renal
symptoms occurring in both preeclampsia as well as VEGF
ablation therapy. To accomplish this we performed a
selective literature search in PubMed database using the
key words “preeclampsia,” “preeclampsia AND protein-
uria,”“preeclampsiaANDpodocyturia,”“preeclampsiaAND
edema,” “preeclampsia AND renal thrombotic microan-
giopathy,” “VEGF ablation therapy,” and “VEGF inhibition
AND renal thrombotic microangiopathy.”
2. Proteinuria
Proteinuria is one of the essential symptoms for the clin-
ical diagnosis of preeclampsia. Any process that induces
a disturbance of the glomerular endothelium, and the
glomerular basement membrane (GBM) or changes in
podocyte function can lead to proteinuria. It has been shown
for many renal diseases that disruptions or an imbalance
of slit diaphragm proteins lead to podocyte eﬀacement
and proteinuria. Podocytes are the major source of VEGF
production in the glomerulus. Podocyte-derived VEGF has
well-documented paracrine functions on endothelial cells as
well as autocrine functions on podocytes themselves [9–11].
However, it remains controversial which VEGF receptor is
most critically involved in autocrine functions of VEGF on
podocytes [12].
Proteinuria and elevations of sFlt-1 that neutralize VEGF
are temporally related in preeclampsia [13] suggesting a
pathophysiological role of sFlt-1 in the development of
proteinuria. However, sFlt-1 levels rise before sings and
symptoms of preeclampsia arise [14].
Renal tissue from autopsy material from preeclamptic
women identiﬁed a reduction in nephrin and synaptopodin
expression in preeclamptic glomeruli [15]. Nephrin and
synaptopodin are podocyte proteins and are essential for
the maintenance of podocyte functions and the integrity of
the slit diaphragm. Similarly, Sugimoto et al. demonstrated
that anti-VEGF antibodies and sFlt-1 caused glomerular
endothelial cell detachment and hypertrophy as well as
downregulation of nephrin [16].
VEGF ablation therapy by bevacizumab (a humanized
monoclonal antibody that recognizes and blocks vascular
endothelial growth factor A (VEGF-A)), sorafenib (a small
molecularinhibitorofseveraltyrosinekinases),sunitinib(an
oral, small-molecule, multitargeted receptor tyrosine kinase
(RTK) inhibitor) and other anti-VEGF drugs are frequently
complicated by mild proteinuria and hypertension. Anti-
VEGF therapy has been associated with the onset of protein-
uriain23%–38%ofpatientswithcolorectalcancerandinup
to 64% of patients with renal cell carcinoma [17]. Although
this proteinuria was largely asymptomatic and low-grade,
high-grade proteinuria and acute kidney injury have been
described in some cases [6, 18].
T h e r ei sap r o f o u n db o d yo fe v i d e n c et h a tV E G Fi s
important in maintaining glomerular endothelial cell health
and healing [19] and that its absence induces proteinuria,
releaseof procoagulantproteins, and glomerularendothelio-
sis [16, 20].
All these studies indicate that neutralization of circulat-
ing VEGF (either by sFlt-1 or antiangiogenetic drugs) may
play an important role in the induction of proteinuria in
cancer therapy and in women with preeclampsia.
3.Podocyturia
Glomerularpodocytesareknowntoregulateproteinuriaand
proteinuria is aften accompanied by podocyturia (excretion
of viable podocytes) that often accompany proteinuria.
Podocyturia is a highly sensitive and speciﬁc marker for
preeclampsia and we were able to demonstrate earlier
together with the Mayo-Clinic that podocyturia may con-
tribute to the development of proteinuria in preeclampsia
[13].
Interestingly a statistical analysis by Aita et al. indicated
a correlation between urinary podocyte number and blood
pressure, but not with proteinuria [21]. Because of the
signiﬁcantcorrelationbetweenbloodpressureandtheextent
of podocyturia Yu et al. saw a causal role of hypertension in
podocyte loss [22].
We earlier demonstrated that urinary loss of podocalyxin
positive cells reﬂects active glomerular damage better than
proteinuria (Achenbach et al. [23]) and we have reported
podocyturia in patients under VEGF ablation therapy with
bevacizumab or sunitinib (M¨ uller-Deile et al. [24]). We
therefore propose that podocyturia is a useful noninvasive
and predictive marker of ongoing glomerular damage in
women with preeclampsia and in patients undergoing VEGF
ablation therapy.
4. Blood Pressure
In a study by Robinson et al. the inhibition of the
VEGF receptor signalling pathway by cediranib (a potent
inhibitor of recombinant KDR tyrosine kinase (VEGFR-
2)) induced a rapid but variable rise in blood pressure
in most patients within three days. Because of the rapid
development of hypertension, acute inhibition of VEGF-
dependent vasodilatation was suggested as explanation [25].
Hertig deﬁned this as a “preeclampsia-like syndrome” in
regard of hypertension and glomerular proteinuria, com-
plicating the treatment with anti-VEGF agents. Quoting
H e r t i gt h i ss y n d r o m ei su s u a l l ym i l do rm o d e r a t ea n d
should be treated by the addition of an antihypertensive
drug while the most severe forms require the interruption
of the regimen [26]. The exact etiology of hypertension
in VEGF ablation therapy is unclear. There are severalJournal of Pregnancy 3
explanations for hypertension in consequence to reduced
VEGF.TheﬁrstindicationsthatVEGFisimportantforblood
pressure regulation came form preclinical studies where Li
et al. could show that VEGFR-2 is the major mediator for
the hypotensive eﬀect of VEGF [27]. VEGF induces the
release of nitric oxide (NO) and prostacyclin (PGI2)b y
endothelial cells leading to vasodilatation [28]. Therefore the
inhibition of VEGF either by sFlt-1 in preeclampsia or by
VEGFablationtherapymayresultinelevatedbloodpressure.
Another cause for hypertension in response to reduced
VEGF may be due to decreased number of small blood
vessels. Decreased density of microvessels leads to increased
peripheral vascular resistance and reduced NO activity.
There may also be an association between therapy-induced
hypertension and proteinuria. Independent of this, VEGF
caninduce hypotension through an endothelial baroreceptor
response [29]. Neutralization of circulating VEGF could
antagonize this eﬀect. Moreover, blocking VEGF signalling
pathway may also interfere with the balance between VEGF
and endothelin which is a potent vasoconstrictor [30].
In contrast to the ﬁndings above recombinant VEGF-
A121 infusion lowered blood pressure and improved renal
function in rats with placental ischemia-induced hyperten-
sion [31].
Li et al. used a virus-infused preeclampsia model that
raises sFlt-1 levels and has been shown to cause renal
glomerularendotheliosis.ByinfusingVEGF-A121,theycould




Edema that can occur during angiogenesis inhibitor therapy
by VEGF ablation is one of the dose-limiting toxicities for
sunitinib. It may also be a direct consequence of the protein-
uria [33]. Edema which is not essential for the diagnosis of
preeclampsia is nevertheless a frequent phenomenon in this
disease.
6.GlomerularCapillaryEndotheliosis
Preeclampsia is associated with a characteristic glomerular
lesion often described as glomerular capillary endotheliosis.
In rats, the reduction in VEGF-A dosage reduces the activa-
tion of endothelial nitric oxide synthase (eNOS) and blocks
the vasodilatation. This contributes to the development of
systemic endotheliosis.
Another suggestion that downregulation of VEGF sig-
nalling within the glomerulus may be involved in the renal
lesion of preeclampsia is given by S. Quaggin’s group: they
described the development of preeclampsia-like endothe-
liosis and “bloodless glomeruli” in mice with podocyte-
speciﬁc heterozygosity for VEGF. By 9 weeks of age, all of the
podocyte-speciﬁc VEGF heterozygotes developed end-stage
kidneyfailureduetoasevereformofglomerulosclerosiswith
loss of diﬀerentiated podocytes and endothelial cells [34].
VEGF-A is also thought to be involved in glomerular
endothelial cell fenestration [35]. In both, preeclampsia and
VEGF ablation therapy reduced dosage of local VEGF-A
led to decreased vasodilatation and reduced formation of
fenestrae.
7. GlomerularThrombotic Microangiopathy
Another parallelity between preeclampsia and VEGF abla-
tion therapy is the risk for thrombotic events especially
thrombotic microangiopathy (TMA) [36, 37]. A case of
histologically documented TMA secondary to sunitinib was
presented by Boll´ ee et al. [38]. Costero et al. reported
a patient who showed arterial hypertension, nephrotic
syndrome, and focal segmental glomerulosclerosis (FSGS) in
addition to TMA ten months after treatment with sunitinib.
The syndrome disappeared six months after sunitinib with-
drawal [39].
Frangi´ e et al. reported the occurrence of TMA in associa-
tion with anti-VEGF antibody treatment for metastatic renal
cell carcinoma [40]. TMA was also seen in association with
VEGF-Trap (a fully humanized recombinant fusion protein
containing extracellular portions of VEGFR-1 and VEGFR-
2) for the treatment of metastatic ovarian cancer [41].
Importantly, Eremina et al. Showed that TMA due to anti-
VEGF treatment is reversible after the drug is withdrawn
[42].
This course is similar to that seen in preeclampsia which
typically resolves after delivery of the placenta when the
source of excess sFlt-1 no longer exists [5].
For preeclampsia Zhang et al. reported a patient
who developed thrombotic microangiopathy secondary to
preeclampsia at 18 week of gestation [43]. Ducroz et al.
found similarities between the clinical, biological, and his-
tological features of thrombotic microangiopathy and the
HELLP syndrome [44]. Interestingly, Verheul and Pinedo
explained the thrombotic events by induction of apoptosis of
endothelial cells due to the blockade of VEGF pathway. The
lack of endothelial cell renewal would in consequence lead to
exposure of thebasementmembrane tothecirculating blood
and result in platelet activation [33].
The hypothesis that external VEGF may accelerate
recovery of renal microvascular injury was studied in an
experimental TMA model. VEGF121 infusion resulted in
greater recovery of the renal microvasculature in rats with
TMA, and eﬀects of VEGF were suggested to be mediated by
NO [45].
These ﬁndings are well in line with the studies of Li et
al. and Gilbert et al., where VEGF also reversed glomerular
lesions.
So in summary, there is a large body of evidence that
the renal involvement in preeclampsia and VEGF ablation
therapy are explained by reduced VEGF levels as illustrated
in Figure 1.
8. Conclusions
As increased serum levels of sFlt-1 are known to be causal
factors for the pathophysiology of preeclampsia, it was
interesting to look at similarities between renal involvement
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Figure 1: Flowchart demonstrates the renal involvement in preeclampsia and VEGF ablation therapy due to decreased levels of local and
circulating VEGF. sFlt-1: soluble fms-like tyrosine kinase-1; VEGF: vascular endothelial growth factor; NO: nitric oxide; PGI2: prostacyclin;
TMA: thrombotic microangiopathy.
A systematic literature review revealed that preeclampsia
a n dV E G Fa b l a t i o nt h e r a p yc a nl e a dt op r o t e i n u r i a ,p o d o c y -
turia, elevated blood pressure, edema, glomerular capillary
endotheliosis, and glomerular thrombotic microangiopathy.
These symptoms and pathologic conditions seem to have
the same etiology because they all can be explained by
decreased VEGF levels (Figure 1). In both preeclampsia and
antiangiogenic tumour therapy the VEGF/PLGF pathway is
either blocked by sFlt-1, therapeutic antibodies against the
growth factors, or VEGF receptor inhibition.
The renal analogy of preeclampsia and side eﬀects of
VEGF ablation therapy could have relevance for future
diagnosis and treatment in both.
As anti-VEGF therapy is becoming more and more
frequent in cancer therapy, preeclampsia provides an exam-
ple where reduced VEGF and PLGF by elevated sFlt-1 are
key factors for disease development. In contrast to tumour
treatment, proangiogenic therapies could repair disturbed
endothelial function in preeclampsia.
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